Drug Profile
Research programme: anti-hepcidin antibodies - Amgen
Alternative Names: 12B9mLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Amgen
- Class Antibodies; Antimicrobial cationic peptides
- Mechanism of Action Antimicrobial cationic peptide modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Anaemia in USA (Parenteral)
- 08 Dec 2009 Preclinical trials in Anaemia in USA (Parenteral)